Investment Analysts’ Recent Ratings Updates for Eli Lilly and Company (LLY)

by · The Cerbat Gem

Eli Lilly and Company (NYSE: LLY) has recently received a number of price target changes and ratings updates:

  • 9/1/2026 – Eli Lilly and Company was upgraded by BMO Capital Markets from “outperform” to “buy”.
  • 8/26/2026 – Eli Lilly and Company was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
  • 8/23/2026 – Eli Lilly and Company was downgraded by Wall Street Zen from “strong-buy” to “buy”.
  • 8/15/2026 – Eli Lilly and Company was upgraded by Wall Street Zen from “buy” to “strong-buy”.
  • 8/11/2026 – Eli Lilly and Company was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
  • 8/7/2026 – Eli Lilly and Company was given a new $1,376.00 price target by UBS Group AG.
  • 8/7/2026 – Eli Lilly and Company had its price target raised by Truist Financial Corporation from $1,370.00 to $1,376.00. They now have a “buy” rating on the stock.
  • 8/6/2026 – Eli Lilly and Company had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $1,419.00 price target on the stock.
  • 8/6/2026 – Eli Lilly and Company had its price target raised by Wells Fargo & Company from $1,280.00 to $1,330.00. They now have an “overweight” rating on the stock.
  • 8/6/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $1,400.00 price target on the stock.
  • 8/6/2026 – Eli Lilly and Company had its price target raised by Cantor Fitzgerald from $1,350.00 to $1,410.00. They now have an “overweight” rating on the stock.
  • 7/18/2026 – Eli Lilly and Company was downgraded by Wall Street Zen from “strong-buy” to “buy”.
  • 7/15/2026 – Eli Lilly and Company had its price target raised by Citigroup Inc. from $1,500.00 to $1,600.00. They now have a “buy” rating on the stock.
  • 7/14/2026 – Eli Lilly and Company had its price target raised by Sanford C. Bernstein from $1,300.00 to $1,385.00. They now have an “outperform” rating on the stock.
  • 7/14/2026 – Eli Lilly and Company had its price target raised by Sanford C. Bernstein from $1,300.00 to $1,385.00. They now have an “outperform” rating on the stock.
  • 7/13/2026 – Eli Lilly and Company had its price target raised by UBS Group AG from $1,250.00 to $1,425.00. They now have a “buy” rating on the stock.
  • 7/13/2026 – Eli Lilly and Company had its price target raised by Guggenheim from $1,235.00 to $1,273.00. They now have a “buy” rating on the stock.
  • 7/10/2026 – Eli Lilly and Company had its price target raised by Bank of America Corporation from $1,251.00 to $1,334.00. They now have a “buy” rating on the stock.
  • 7/9/2026 – Eli Lilly and Company was given a new $1,370.00 price target by UBS Group AG.
  • 7/8/2026 – Eli Lilly and Company had its price target raised by Truist Financial Corporation from $1,281.00 to $1,370.00. They now have a “buy” rating on the stock.
  • 7/8/2026 – Eli Lilly and Company had its price target raised by Morgan Stanley from $1,344.00 to $1,347.00. They now have an “overweight” rating on the stock.
  • 7/8/2026 – Eli Lilly and Company had its price target raised by Royal Bank Of Canada from $1,250.00 to $1,500.00. They now have an “outperform” rating on the stock.
  • 7/7/2026 – Eli Lilly and Company had its price target raised by JPMorgan Chase & Co. from $1,300.00 to $1,400.00. They now have an “overweight” rating on the stock.
  • 7/6/2026 – Eli Lilly and Company had its price target raised by Cantor Fitzgerald from $1,230.00 to $1,350.00. They now have an “overweight” rating on the stock.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 23.22%.

Insider Transactions at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock valued at $15,958,170 in the last 90 days. 0.14% of the stock is currently owned by insiders.

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Featured Articles